Increasingly, research is showing that gut flora (gut bacteria) play a role in our health.
For example, arthritis researchers at NYU School of Medicine think they may have found a new clue to help understand the cause of rheumatoid arthritis.
The NYU researchers examined the fecal samples of those living with rheumatoid arthritis, and for comparison, also looked at the poop of healthy people. They discovered that those newly diagnosed with RA had more P. copri (Prevotella copri) than people either without RA or living with treated rheumatoid arthritis. Also, though it is typically a beneficial gut bacteria, the researchers found that when there was an overgrowth of P. copri, there were also fewer of another group of beneficial gut bacteria (of the genera Bacteroides).
It has not yet been concluded that the overabundance of P. copri causes rheumatoid arthritis; however, the researchers think problems may occur because this imbalance in gut flora interferes with the immune system and causes it to malfunction. How this happens still needs to be worked out in further studies.
For details about this fascinating study, please check out this article on the website Science Codex.
Certolizumab Pegol (Cimzia®) for the treatment of rheumatoid arthritis approved in Quebec.
As of October 1st, certolizumab pegol (Cimzia®) for the treatment of moderate to severe rheumatoid arthritis has been listed for coverage on Quebec’s drug formulary. Click here to view the detailed medication criteria.
Now there are more treatment options available in Quebec, which is important because every patient responds differently to disease suppressing or modifying medications.
Certolizumab pegol is an anti-TNF medication taken by subcutaneous injection every two weeks. To learn if certolizumab pegol or other rheumatoid arthritis treatment may be helpful to you, please speak to your rheumatologist or other healthcare provider who is helping you to manager your disease.
Click here to view the most up-to-date version of ACE’s Report Card on provincial formulary reimbursement listings for biologic response modifiers.
Le comité ACE (Arthritis Consumer Experts) veut transmettre vos questions aux experts.
Cet événement annuel est une première du genre puisqu’il regroupe en un seul événement plus de 12 500 rhumatologues et professionnels de la santé en rhumatologie. Les membres de l’ACR peuvent participer et échanger les renseignements les plus récents en matière de médicaments, de découvertes et de recherche dans le domaine des maladies rhumatismales.
Cette année, le comité ACE sera sur place et a l’intention de suivre les séances de présentations par affiches, le cours de revue de notions de l’ACR et d’assister à autant de sessions scientifiques que possible.
This annual event is the world’s premiere meeting of over 12,500 rheumatologists and rheumatology health professionals in one venue. ACR members can participate and share the latest information related to rheumatic disease treatments, advances and research.
Arthritis Consumer Experts (ACE) will be attending this year. ACE plans to attend poster sessions, the ACR review course and take in as many scientific sessions as possible.
A recent Dutch research study shows that rheumatoid arthritis (RA) patients with a low baseline levels of folate in their red blood cells responds less to treatment with methotrexate. Researchers say that these patients have more active disease at three months despite their treatment.
Folate is one of the B vitamins that play a role in the making of DNA and RNA. It is also important for repairing tissues like blood vessels and manufacturing red blood cells. Continue reading →
On September 19, Arthritis Consumer Experts (ACE) encouraged community members with rheumatoid arthritis (RA) to participate in a physical activity study with the Arthritis Research Centre of Canada (ARC). To show support for our community, Cheryl Koehn, President and Founder of ACE was amongst the first to sign up!
As one of the study participants, Cheryl has been asked to test two different activity trackers over a 4-week period. The first tracker is called the FitBitTM Flex, a wrist-worn activity monitor that measures an individual’s physical activity. The tracker allows users to create personalized fitness goals and integrate their goals with social media such as Facebook, Twitter and email. Continue reading →